Skip to main content
NKMAX Co., Ltd. logo

NKMAX Co., Ltd. — Investor Relations & Filings

Ticker · 182400 ISIN · KR7182400002 KO Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2025-09-03 Regulatory Filings
Country KR South Korea
Listing KO 182400

About NKMAX Co., Ltd.

https://nkmax.com/

NKMAX Co., Ltd. is a biotechnology company focused on developing immune-based solutions centered on Natural Killer (NK) cells. The company's primary focus is the development of adoptive cell therapies to treat incurable diseases, including cancer, autoimmune disorders, and neurodegenerative conditions. Its portfolio includes anti-cancer immunotherapy treatments and other biological products. In addition to therapeutics, NKMAX develops and markets a precision diagnostic test that measures NK cell activity. The company also manufactures and supplies specialized reagents, such as high-quality recombinant proteins and antibodies, for biotechnology research, as well as a line of health functional foods designed to support the immune system.

Recent filings

Filing Released Lang Actions
기타시장안내 (실질심사 대상여부 결정을 위한 조사기간 연장 안내 )
Regulatory Filings Classification · 100% confidence The document is a short regulatory notice from the Korea Exchange regarding NKMAX. It informs the market about an extension of the investigation period for determining the company's eligibility for continued listing (delisting review). Since it is a regulatory announcement regarding a legal/compliance process and does not fit into specific categories like M&A or financial reports, it is classified as a general regulatory filing.
2025-09-03 Korean
회생절차종결신청
Legal Proceedings Report Classification · 100% confidence The document is an official regulatory filing from the Korea Exchange (KRX) regarding a company's application to terminate rehabilitation proceedings (회생절차 종결신청). This is a significant corporate event involving legal and financial restructuring status. Since it does not fit into specific categories like M&A (which is mentioned as a past event) or financial reports, and it is a formal regulatory disclosure, it falls under the 'Regulatory Filings' category.
2025-08-25 Korean
대표이사변경
Board/Management Information Classification · 100% confidence The document is an official announcement regarding the change of the company's CEO (Representative Director). It details the former and new CEO, the reason for the change (rehabilitation plan), and the effective date. This falls directly under the category of Board/Management Information.
2025-08-14 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a formal regulatory filing titled '사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고' (Report on the Appointment, Dismissal, or Resignation of Outside Directors). It details specific changes to the company's board of directors, including the names of the directors, their roles, and the reasons for their departure or appointment. This falls directly under the category of Board/Management Information (MANG).
2025-08-14 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company 'NKMAX' covering the period from January 1, 2025, to June 30, 2025. It contains detailed financial information, business operations, management discussions, and corporate governance details. This fits the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial data for a period shorter than a full fiscal year. H1 2025
2025-08-14 Korean
반기검토(감사)의견부적정등사실확인(자본잠식률100분의50이상또는자기자본10억원미만포함)
Audit Report / Information Classification · 100% confidence The document is a regulatory disclosure from a Korean company (NKMAX) regarding the confirmation of audit opinions and financial status (specifically capital impairment). It is a formal regulatory filing submitted to the KRX (Korea Exchange) detailing audit results and financial metrics for the semi-annual period. While it references a 'Semi-Annual Report', the document itself is a specific regulatory disclosure form regarding audit findings and capital status, which falls under the 'Regulatory Filings' category as it is a mandatory disclosure of specific financial events rather than the full report itself. H1 2025
2025-08-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.